Oncolytic Viral Therapy for Human Prostate Cancer by Conditionally Replicating Herpes Simplex Virus 1 Vector G207

Over the last few years, a conditionally replicating herpes simplex virus 1 (HSV‐1) vector, G207 has been used for the treatment of several malignant tumors. In this article we evaluate the antitumoral effect of G207 against prostate cancer in vitro and in vivo. The susceptibility of the human prost...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2000-12, Vol.91 (12), p.1339-1344
Main Authors: Oyama, Masafumi, Ohigashi, Takashi, Hoshi, Michio, Murai, Masaru, Uyemura, Keiichi, Yazaki, Takahito
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Carcinogenesis, carcinogens and anticarcinogens
Cell Division
Gene therapy
Genetic Therapy - methods
Genetic Vectors
Health risk assessment
Herpes simplex
Herpes simplex virus
Herpes viruses
Herpesvirus 1, Human - genetics
Herpesvirus 1, Human - physiology
Humans
Inoculation
Male
Medical sciences
Mice
Mice, Nude
Multiplicity of infection
Oncolysis
Oncolytic virus
Prostate cancer
Prostate neoplasms
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Replication‐competent virus
Transfection
Tumor cell lines
Tumor Cells, Cultured
Tumors
Virus Replication
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the last few years, a conditionally replicating herpes simplex virus 1 (HSV‐1) vector, G207 has been used for the treatment of several malignant tumors. In this article we evaluate the antitumoral effect of G207 against prostate cancer in vitro and in vivo. The susceptibility of the human prostate cancer cell lines, DU145 and PC3 to G207 at a multiplicity of infection (MOI) of 0.1 was examined. In addition, the growth characteristics of G207 were assessed. Athymic mice with s.c. tumors were inoculated in vivo intraneoplastically with 1x107 plaque‐forming units (PFU) of G207. For the pathological analyses, s.c. tumors were stained with X‐gal. DU145 and PC3 were efficiently destroyed by G207 within 7 days. The viral yields of G207 increased time‐dependently. In vivo, the intraneoplastic inoculation of G207 induced a significant inhibition of the tumor growth. The mean tumor growth ratio was significantly inhibited in the G207‐treated tumors (DU145, P< 0.0001; PC3, P < 0.001 versus controls). In a pathological study, many lacZ‐positive cells were diffusely present in the G207‐treated tumors. G207 showed a significant antitumoral effect against human prostate cancer cell lines, and thus may be considered a useful agent for the treatment of prostate cancer.
ISSN:0910-5050
1347-9032
1349-7006
1876-4673
DOI:10.1111/j.1349-7006.2000.tb00923.x